← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2001Last known activity
Jul 31, 2026
Timeline
1980s
- Jun 1, 1989
Miltenyi Biotec, Inc.— Founded
2000s
- Jun 2, 2003
Eligix— Acquired
Drugs by trial phase (50 distinct, 44 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (32 own, 0 via acquisition)
Phase 1 (11 own, 0 via acquisition)
Other trials (1 own, 1 via acquisition)
Indications
Studied for
- Anaphylaxis
- Anemia, Aplastic
- Anemia, Sickle Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Communicable Diseases
- Coronary Artery Disease
- Crohn Disease
- Cytomegalovirus Infections
- Food Hypersensitivity
- Graft vs Host Disease
- Hodgkin Disease
- Infections
- Ischemia
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myocardial Infarction
- Myocardial Ischemia
- Neoplasms
- Neoplasms, Plasma Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Squamous Cell Carcinoma of Head and Neck
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (43)
- NCT01881334CollaboratorN/A—
- NCT07153289CollaboratorPhase 1/Phase 2Jul 31, 2026
- NCT07178431Lead sponsorPhase 1/Phase 2Jan 30, 2026
- NCT07288879Lead sponsorPhase 2Dec 10, 2025
- NCT07192900CollaboratorPhase 1Oct 31, 2025
- NCT07137494CollaboratorPhase 1Aug 14, 2025
- NCT06508931Lead sponsorPhase 2Apr 1, 2025
- NCT06708845Lead sponsorPhase 1Jan 31, 2025
- NCT06189157Lead sponsorPhase 1/Phase 2Aug 12, 2024
- NCT06424340Lead sponsorPhase 1/Phase 2Aug 1, 2024
- NCT06508775Lead sponsorN/AMay 5, 2024
- NCT05705570CollaboratorPhase 1Mar 1, 2023
- NCT04881682CollaboratorPhase 2Jan 1, 2022
- NCT04812470CollaboratorPhase 1Nov 1, 2021
- NCT04844866Lead sponsorPhase 2Aug 18, 2021
Details
- Founded
- Bergisch Gladbach, DE Jun 1, 1989
- Last known activity
- Jul 31, 2026